SY-5609
Highest phase reached
Phase 1
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 1
- Drug type
- Small molecule
- Drug name
- SY-5609
- Molecular weight
- 490.47
- Structure (SMILES)
- CC1(C)CC[C@H](Nc2ncc(C(F)(F)F)c(-c3c[nH]c4c(P(C)(C)=O)c(C#N)ccc34)n2)CN1
- sy 5609
- Sy 5609
- SY 5609 [WHO-DD]
- sy 5609 who dd
- Sy-5609
- SY-5609
- sy5609
- SY5609
- CAS registry numbers
- 2417302-07-7
- ChEMBL ID
- CHEMBL5090754
- InChIKey
- JDJOUBVVSQDIRC-AWEZNQCLSA-N
- PubChem compound IDs
- 146662729
- FDA ingredient codes (UNII)
- TW6044C3O6
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- SY-5609
- Type
- Synthetic organic
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- cyclin dependent kinase 7
- Gene symbol
- CDK7
- Protein identifier
- P50613
- Median affinity
- 7.15
- Affinity units
- pKd
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- cyclin dependent kinase 9
- Gene symbol
- CDK9
- Protein identifier
- P50750
- Median affinity
- 5.72
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- cyclin dependent kinase 12
- Gene symbol
- CDK12
- Protein identifier
- Q9NYV4
- Median affinity
- 5.77
- Affinity units
- pIC50
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Breast Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 1
Trial references
- NCT04247126
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 3
- Polar surface area
- 106.49
- Calculated partition coefficient (ALogP)
- 4.71
- Calculated partition coefficient (XLogP)
- 2.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 34
- Molecular formula
- C23H26F3N6OP
- Monoisotopic mass
- 490.18578096
- Natural product
- No
- Recorded assays
- 244
- Active assays
- 118
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (2)
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
In development for (4)
- Breast cancer Phase 1
- Exocrine pancreatic carcinoma Phase 1
- Neoplasm Phase 1
- Small cell lung carcinoma Phase 1